Literature DB >> 1063592

Lack of prognostic value of lymphoblast size in acute lymphoblastic leukaemia.

M W Oster, D A Margileth, R Simon, B G Leventhal.   

Abstract

There are conflicting reports about the relationship of cell size and type to prognosis in acute lymphoblastic leukaemia (ALL). For this reason, bone marrows at diagnosis and first relapse were studied in 56 children with ALL treated on the same protocol. Lymphoblasts greater than 12 mmu in diameter were called macrolymphoblasts (MLB). Forty-one of 56 initial bone marrows had less than 20% MLB(group A), and 15 had greater than 20% MLB (group B). Median survival, complete remission rate, first remission duration, and the distribution of CNS leukaemia were similar in both groups. First relapse marrows were examined from 50 patients and a significant increase in MLB compared to initial pre-treatment bone marrows (18% vs 8%) was found.

Entities:  

Mesh:

Year:  1976        PMID: 1063592     DOI: 10.1111/j.1365-2141.1976.tb00979.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  4 in total

1.  Editorial: Prognostic factos in childhood leukaemia.

Authors: 
Journal:  Br Med J       Date:  1976-08-14

2.  Prognosis and treatment of acute lymphoblastic leukemia. Study of 650 patients.

Authors:  C Jacquillat; M Weil; M F Auclerc; C Chastang; G Flandrin; V Izrael; G Schaison; L Degos; M Boiron; J Bernard
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

3.  Lymphoblast cell size and prognosis in acute lymphoblastic leukemia in childhood.

Authors:  G E Janka; S Teige-Singer; R J Haas; B M Lau
Journal:  Blut       Date:  1978-08-15

4.  Relationship between the pretreatment proliferative activity of marrow blast cells and prognosis of acute lymphoblastic leukaemia of childhood.

Authors:  J H Scarffe; I M Hann; D I Evans; P Morris Jones; M K Palmer; J S Lilleyman; D Crowther
Journal:  Br J Cancer       Date:  1980-05       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.